万孚生物(300482) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was ¥662,780,396.16, representing a year-over-year increase of 1.83%[7] - Net profit attributable to shareholders for the same period was ¥61,975,646.69, a decrease of 13.40% compared to the previous year[7] - The net profit after deducting non-recurring gains and losses was ¥41,958,980.16, down 19.65% year-over-year[7] - The basic earnings per share for Q3 2022 was ¥0.14, a decrease of 12.50% year-over-year[7] - Total operating revenue for the current period reached ¥4,696,406,530.65, a significant increase from ¥2,507,113,200.58 in the previous period, representing an increase of approximately 87.0%[28] - Net profit attributable to shareholders of the parent company was ¥1,239,862,956.82, compared to ¥627,236,534.10 in the previous period, marking an increase of about 97.4%[30] - Comprehensive income for the current period totaled ¥1,245,422,260.47, compared to ¥626,099,669.01 in the previous period, an increase of approximately 99.0%[33] - Basic earnings per share rose to ¥2.81 from ¥1.42, representing an increase of about 97.2%[33] Assets and Liabilities - Total assets at the end of the reporting period reached ¥6,271,926,433.32, an increase of 29.16% compared to the end of the previous year[7] - The company's total liabilities as of September 30, 2022, were CNY 1,600,873,088.00, compared to CNY 1,351,752,059.03 at the beginning of the year, marking an increase of about 18.4%[24] - Total assets amounted to ¥6,271,926,433.32, up from ¥4,855,824,467.37 in the previous period, indicating a growth of approximately 29.1%[27] - The company's total liabilities increased to ¥1,600,873,089.00 from ¥1,351,752,059.03, reflecting a rise of about 18.4%[27] Cash Flow - The company's cash flow from operating activities showed a significant increase of 298.59%, totaling ¥1,076,944,403.73[7] - The net cash flow from operating activities for the current period is CNY 1,076,944,403.73, a significant increase from CNY 270,188,527.22 in the previous period, reflecting a growth of approximately 298%[34] - Total cash outflow from operating activities was CNY 3,650,907,969.34, compared to CNY 2,134,993,551.39 in the previous period, reflecting an increase of approximately 71%[34] - Cash received from sales of goods and services reached CNY 4,591,619,656.34, up from CNY 2,321,864,556.73, marking an increase of about 98%[34] - Cash inflow from financing activities increased to CNY 279,485,215.78 from CNY 72,987,212.53, representing an increase of about 283%[36] - The net cash flow from financing activities improved to CNY 65,364,977.83 from CNY -272,201,846.67, indicating a positive turnaround[36] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 58,302, with the largest shareholder holding 22.01% of the shares[14] - The company reported a total of 147,438,708 shares held by the controlling shareholders, accounting for 33.17% of the total share capital[18] - The company had a total of 750,750 restricted shares at the end of the period, down from 1,199,900 at the beginning of the year, indicating a reduction of about 37.4%[20] Investments and Expenses - Research and development expenses for the current period were ¥309,398,871.02, compared to ¥276,627,339.80 in the previous period, an increase of approximately 11.8%[28] - The company reported a net exchange gain of ¥8,305,850.54, compared to a loss of ¥351,782.11 in the previous period[33] - The company recorded a financial asset derecognition gain of ¥3,729,830.14, with no gain reported in the previous period[30] - The company received government subsidies amounting to ¥19,205,959.57 during the reporting period[8] Asset Composition - The company's current assets reached CNY 3,096,095,164.44, up from CNY 2,585,511,622.89 at the start of the year, indicating a growth of approximately 19.7%[21] - The accounts receivable increased to CNY 633,348,509.34 from CNY 498,321,965.11, representing a growth of approximately 27.0%[21] - The long-term equity investments rose to CNY 347,390,762.21 from CNY 333,697,569.65, showing a slight increase of approximately 4.1%[24] - The company's fixed assets increased to CNY 983,705,339.18 from CNY 851,740,520.74, indicating a growth of about 15.5%[24] - The total non-current assets reached CNY 3,175,831,268.88, up from CNY 2,270,312,844.48, reflecting an increase of approximately 39.9%[24]